INTRODUCTION

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that affects 3%–6% of individuals in the general population and has no available FDA-approved medicines.1 Although the 'two-hit' theory is well acknowledged in the field,2 novel pathway discovery in NASH pathogenesis is in high demand. A recent review emphasized the contribution of hepatocyte-macrophage-stellate cell crosstalk in fibrogenesis,3 and another report recognized hepatic stellate cells (HSCs) as a hub of intracellular signalling via stellakine secretion.4 Unfortunately, the detailed signalling within a specific cell type and complex crosstalk among non-parenchymal cell (NPC) types are still largely unknown. Consequently, further understanding of how different cell types contribute to NASH pathogenesis is urgent for the identification of novel therapeutic targets.

To date, several methods have been established for liver cell subtype isolation, most in normal livers.5,6 The key step is density gradient centrifugation after a two-step collagenase perfusion.7 However, due to the density similarity between liver endothelial cells (LECs) and hepatic stellate cells (HSCs), this method alone failed to achieve satisfying purity. Furthermore, due to the physiological and biological changes of diseased liver cells, especially HSCs, the isolation of cells from normal and disease livers using the reported protocol is challenging, and isolated cell types are limited.8,9 Fernández-Iglesias and colleagues described a high-purity method in isolating hepatocytes, LECs,
HSCs and macrophages simultaneously in healthy and cirrhotic rat livers via centrifugation and sequential plating on coated dishes. This method is applicable for in vitro study but not for experiments geared towards understanding in vivo biology. Currently, no methods have been reported to isolate both parenchymal and non-parenchymal cell types in NASH livers for in vivo biology study.

Here, utilizing single-cell RNA sequencing-based cell surface markers, we describe a technique that can simultaneously isolate five key cell types in one liver from healthy and NASH mouse models with high purity, enabling the accuracy of downstream mechanistic studies within or among cell types.

2 | METHODS

2.1 | Animals and NASH models

10-week-old male C57BL/6NTac mice purchased from Taconic Biosciences were housed at Regeneron Pharmaceuticals under standard condition. Mice were fed ad libitum with standard chow (Purina Laboratory, Rodent diet 5001) or high-fat high-fructose diet (HFHFD) (D09100310i; Research Diets Inc.). For NASH models, mice were fed with HFHFD for 25–30 weeks or HFHFD with intraperitoneal injection of CCL4 (Sigma-Aldrich) at a concentration of 0.2ml/kg twice per week for 10 weeks. The vehicle group was fed with chow diet and injected with the same volume of corn oil.

2.2 | Liver perfusion and digestion

Mice were anaesthetized and perfused with the Liver Perfusion Buffer (Gibco) and then digestion buffer (HBSS containing 5 mM CaCl2, 10 mM HEPES and 0.2 mg/ml collagenase I & II (Liberase TM, Roche)). After digestion, the liver was excised and maintained in the Hepatocyte Wash Media (Gibco) on ice.

2.3 | Isolation of hepatocytes and non-parenchymal cells

Hepatocytes were released from liver lobes and then filtered through 70-μm cell strainers (Corning). After centrifugation and wash, hepatocytes were resuspended in 40% (chow) or 30% (NASH) Percoll (Sigma) in Williams E Media (Gibco) and centrifuged to collect live hepatocytes on the bottom (Figure 1A).

The remaining liver lobes were minced and further digested by 2.5 mg/mL collagenase D (Roche) and 100 ng/mL DNase I (Sigma) at 37°C for 20–30 min. After centrifugation and wash, NPC pellets were loaded on top of Percoll gradient layers (10mL 15% Percoll on the top and 10mL 40% Percoll on the bottom) for further centrifugation. NPC layer in the middle was collected (Figure 1A).

2.4 | NPC cell sorting and imaging

NPCs were incubated with Fc-receptor blocking antibody first, then subsequently stained with antibodies anti-CD31, anti-CD45, anti-F4/80 and anti-CD140b (Table S1) for sorting. Sorts were performed on BD FACSAria™ Fusion. An unstained hepatocyte sample was run to minimize hepatocyte contamination in the collected fractions.

2.5 | Statistical analysis

Data were normalized from three independent experiments. All data were analysed by GraphPad Prism software.

For more methods, please refer to Supplementary Material.

3 | RESULTS

3.1 | Mice on HFHFD and HFHFD+CCL4 developed NASH phenotype

As shown in Figure S1, the two NASH models developed NASH histology hallmarks, including liver steatosis, inflammation and fibrosis (Figure S1).

3.2 | Yield and viability

As shown in the FACS plots (Figure 1), different cell types were isolated from both chow and NASH livers. Using this method, we were able to isolate hepatocytes >90% viability from mice on chow and >75% viability from mice on NASH models. The viability of NPCs was consistently >99% across all isolated cell types from chow and NASH models. Cell yields were variable among different cell types (Table S2).

3.3 | High purity of isolated cells from normal and NASH livers

To test the purity of yield, we performed gene expression and morphological studies on isolated cells (Figure 2A-I & Figure S3A-F). In RT-PCR, the purity of each cell type was evaluated by the expression of cell type markers identified through scRNA-seq (Figure S2). We observed an estimate >95% of purity of each cell type. For example, compared to HSCs, non-HSC cells expressed less than 3.77% and 3.27% of HSC marker CD140b and collagen type III alpha 1 chain (Col3a1) respectively (Figure 2E-F & Figure S3E-F). Morphological studies on cultured hepatocytes revealed a pronounced lipid accumulation on hepatocytes isolated from HFHFD mice (Figure 2G). More than 95.1% of normal and 94.1% of steatotic hepatocytes were albumin-positive (Figure 2H). Images of single NPC cells captured
from flow cytometry showed clear cell surface marker staining (Figure 2I).

4 | DISCUSSION

Though NASH affects 3–6% of individuals in the United States, deep understanding of its pathogenesis is limited. Liver cell type isolation has been achieved by multiple methods, but none of these techniques were applied to NASH livers. Here, we report a Five-in-One method that can simultaneously isolate five cell types in healthy and NASH livers.

We could not isolate HSCs by autofluorescence alone or autofluorescence+/CD45- (Figure S4), a method suggested by Tacke and Schwabe groups.8,9 This is likely due to the disparity of isolation purpose and protocol. Both methods enriched HSCs at the expense of other cell types, while our goal was to retain all NPCs, especially macrophages that emit overwhelming autofluorescence. On top of
that, HSCs significantly decrease autofluorescence intensity upon activation in NASH; therefore, we believe cell surface marker-based, rather than autofluorescence-based, cell sorting is a better choice for NASH HSC isolation.

Although our method achieved its primary goals, several limitations need to be considered. NPC isolation procedures with enzyme digestion followed by antibody staining and sorting may affect the expression of some genes, rapid signalling events and post-translational modification process. In addition, this method requires sophisticated skills from the researcher and established platform from the institute, which could be costly regarding labour and equipment expense. Finally, the yield of NPCs, especially HSCs, may not be adequate for downstream applications requiring large amount of material, such as biochemistry studies.

This method requires only a single liver for all five cell types, significantly reducing the number of animals used and assuring an accurate comparison within one animal. The isolated cells can be further processed with RNA analyses and cell-culture studies for pathogenesis investigation and drug screening. Our method facilitates the opportunity for a deeper understanding of different cell types and their specific signalling pathways, cell-cell interactions and contributions to pathogenesis, which may lead to the discovery of novel drug targets.

ACKNOWLEDGEMENT

We thank Sean D’Italia and Dominic Vergata for their help in sample harvesting.

CONFLICT OF INTEREST

The authors declare no conflicts of interest to disclose. All authors are employees and shareholders of Regeneron Pharmaceuticals.

AUTHOR CONTRIBUTIONS

Ye Zhou: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Investigation (lead); Methodology (lead); Project administration (lead); Writing-original draft (lead). Funmilola Adewale: Conceptualization (supporting); Data curation (equal); Formal analysis (equal); Methodology (equal); Writing-review & editing (equal). Sun Kim: Conceptualization (equal); Methodology (equal); Writing-review & editing (equal). Qi Su: Data curation (equal); Formal analysis (equal); Software (lead); Writing-review & editing (supporting). David Glass: Conceptualization (equal); Project administration (supporting); Supervision (equal); Writing-review & editing (equal). Mark W. Sleeman: Conceptualization (equal); Project administration (equal); Supervision (equal); Writing-review & editing (equal). Andrew J. Murphy: Conceptualization (equal); Project administration (supporting); Supervision (equal). Xiping Cheng: Conceptualization (equal); Investigation (equal); Methodology (equal); Project administration (lead); Supervision (lead); Writing-review & editing (lead).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Ye Zhou https://orcid.org/0000-0003-3861-3120

REFERENCES

1. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175-1183.
2. Friedeman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922.
3. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020;158(7):1913-1928.
4. Xiong X, Kuang H, Ansari S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell. 2019;75(3):644-660 e645.
5. Pfeiffer E, Kegel V, Zeilinger K, et al. Featured Article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood). 2015;240(5):645-656.
6. Damm G, Pfeiffer E, Burkhardt B, Vermeulen J, Nussler AK, Weiss TS. Human parenchymal and non-parenchymal liver cell isolation, culture and characterization. Hepatol Int. 2013;7(4):951-958.
7. Liu W, Hou Y, Chen H, et al. Sample preparation method for isolation of single-cell types from mouse liver for proteomic studies. Proteomics. 2011;11(17):3556-3564.
8. Mederacke I, Dapito DH, Affo S, Uchinami H, Schwabe RF. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat Protoc. 2015;10(2):305-315.
9. Barneck M, Warzecha KT, Tag CG, et al. Isolation and time lapse microscopy of highly pure hepatic stellate cells. Anal Cell Pathol (Amst). 2015;2015:417023.
10. Fernandez-Iglesias A, Ortega-Ribera M, Guixe-Muntet S, Gracia-Sancho J. 4 in 1: Antibody-free protocol for isolating the main hepatic cells from healthy and cirrhotic single rat livers. J Cell Mol Med. 2019;23(2):877-886.
11. Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018;69(2):385-395.
12. Khomich O, Ivanov AV, Bartosch B. Metabolic hallmarks of hepatic stellate cells in liver fibrosis. Cells. 2019;9(1):24.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Zhou Y, Adewale F, Kim S, et al. Five-in-One: Simultaneous isolation of multiple major liver cell types from livers of normal and NASH mice. J Cell Mol Med. 2021;25:9878–9883. https://doi.org/10.1111/jcmm.16933